The central nervous system (CNS) tumors are those of the brain and spinal cord including the meninges, pituitary gland, pineal gland, and nerves according to the 3rd edition of the International Classification of Diseases for Oncology (ICD-O-3) (<http://codes.iarc.fr/>). The incidence rate of all primary malignant and nonmalignant CNS tumors in the United States was 22.36 cases per 100,000 (5.67/100,000 for 0--14 years, 5.71/100,000 for 0--19 years) according to the U.S. Central Brain Tumor Registry (CBTRUS; <http://www.cbtrus.org/factsheet/factsheet.html>). The proportion of women with CNS tumors is higher than that of men (1.2:1). In the United States, the number of newly diagnosed primary malignant and nonmalignant CNS tumors is expected to reach 79,270 (26,070 cases of primary malignant and 53,200 cases of nonmalignant tumors) by 2017. The average annual mortality rate in the United States between 2009 and 2013 is 4.32 per 100,000 and with 73,450 deaths attributed to primary malignant brain and other CNS tumors. If we extrapolate the U.S. data with its incidence rate to the Korean population, per year we would expect about 12,500 new cases of primary CNS tumors and 2,160 deaths. According to the nationwide cancer registration (hospital based Korean Central Cancer Registry \[KCCR\], <http://www.iacr.com.fr/index.php?option=com_comprofiler&task=userprofile&user=973&Itemid=498>, <http://ncc.re.kr/cancerStatsView.ncc?bbsnum=358&searchKey=total&searchValue=&pageNum=1>), 10,004 patients were diagnosed with primary CNS tumors in Korea in 2010, which means that the incidence of brain tumors in Korea is lower than that of United States \[[@b1-jptm-2017-03-08],[@b2-jptm-2017-03-08]\]. Similar to the United States, CNS tumors occurred more frequently in female (female:male, 1.59:1). The four most common tumors were meningioma (35.5%), pituitary tumors (18.7%), gliomas (15.1%), and nerve sheath tumors (10.3%). Glioblastoma (GBM) is the most common and the most malignant glioma, which comprises 34.6% of all gliomas. In children (0--19 years), sellar region tumors (pituitary adenoma and craniopharyngiomas), pilocytic astrocytomas, germ cell tumor, and embryonal tumors/medulloblastoma were the most common brain tumors \[[@b2-jptm-2017-03-08]\].

The 5-year relative survival rate in the United States after the diagnosis of brain or other CNS tumors that are either primary malignant or nonmalignant is 34.7% and 90.4%, respectively. The survival rate of patients with malignant CNS tumors depends on onset age, histologic and molecular diagnosis, and the tumor grade. The overall survival rate decreases with age (0--19 years, 73.8%; 20--44 years, 61.5%; 45--54 years, 33.5%; 55--64 years, 18.5%; 65--74 years, 11.2%; 75 or older: 6.3%). Therefore, children are more likely to survive than adults after malignant CNS tumors develop. Thus, advances must be made to improve the survival rates of young patients with CNS tumors.

The completion of the human genome project led to two powerful tools: the human genome sequence and advanced molecular technologies. Over the past few decades, investigators have been constantly searching for causes of cancer. Through high-throughput studies such as the Cancer Genome Atlas (TCGA) project (<https://cancergenome.nih.gov/>) or the cBio-Portal project (<http://www.cbioportal.org/>), a large number of brain tumors have been sequenced and major genetic alterations in brain tumors have been identified \[[@b3-jptm-2017-03-08]\], thus allowing for the classification of gliomas. The signaling pathways that are mainly involved in GBM are RTK/RAS/phosphoinositide 3-kinase (PI3K) signaling, p53 signaling, and Rb signaling, which were identified through analyses of common mutations and copy number variations (CNV) in gliomas \[[@b4-jptm-2017-03-08]\]. In addition, according to the molecular classification by global mRNA expression and DNA methylation, GBMs can be categorized into neural, proneural, classical, and mesenchymal transcriptomic subtypes \[[@b5-jptm-2017-03-08]\].

One of the most prominent molecular discoveries was made in 2008 in the genomics of diffuse gliomas. Mutations in *IDH1* and *IDH2* were discovered by whole exome sequencing (WES) of GBMs, thus altering the classification of gliomas \[[@b6-jptm-2017-03-08]\]. *IDH1* or *IDH2* mutations are found in both astrocytic and oligodendroglial tumors since they act as a starting point for gliomagenesis. Therefore, the 2016 World Health Organization (WHO) classification guidelines combined astrocytic tumors and oligodendroglial tumors into one category \[[@b7-jptm-2017-03-08]-[@b10-jptm-2017-03-08]\]. Furthermore, each tumor has a typical genetic signature. For example, oligodendrogliomas are characterized by a codeletion in 1p/19q, mutations in *IDH*, and the promoter region of the gene encoding telomerase reverse transcriptase (*TERTp*). Furthermore, grade 2 and grade 3 astrocytic tumors are characterized by *ATRX* and *TP53* mutations, while IDH-wildtype (primary) GBMs are characterized by the CNV of *EGFR*, *PTEN*, **CDKN2A*/B*, *PDGFRA*, and *MET* genes, in addition to a lack of mutations in*IDH* and a codeletion in 1p/19q \[[@b11-jptm-2017-03-08]-[@b13-jptm-2017-03-08]\].

Even in tumors that are morphologically similar, those with mutations in*IDH* and a codeletion in 1p/19q differ in the treatment response and prognosis compared with tumors without these two molecular alterations \[[@b11-jptm-2017-03-08],[@b14-jptm-2017-03-08]-[@b19-jptm-2017-03-08]\]. Since only gliomas with mutations in*IDH* and a codeletion in 1p/19q are considered oligodendrogliomas, the so-called pediatric-type oligodendroglioma lacking these two alterations is not considered an oligodendroglioma. The molecular differences of primary IDH-wildtype and IDH-mutant (secondary) GBMs are well summarized in the paper by Cachia *et al*. \[[@b20-jptm-2017-03-08]\]. The genetic abnormalities of the IDH-mutant GBMs are similar to grade II/III astrocytomas. In other words, they more likely have mutations in *IDH*, *ATRX*, and *TP53*.

Since the prognosis of each tumor depends on the mutational status of *IDH1* and *IDH2*, astrocytic tumors are also classified according to this metric ([Fig. 1](#f1-jptm-2017-03-08){ref-type="fig"}) \[[@b6-jptm-2017-03-08],[@b8-jptm-2017-03-08],[@b21-jptm-2017-03-08]\]. Pediatric GBMs and high-grade gliomas differ from those of adults. No genetic abnormalities in *IDH1* and *IDH2* are found in pediatric GBMs, but mutations are generally found in *H3F3A*, *ATRX* and *DAXX* ([Fig. 2](#f2-jptm-2017-03-08){ref-type="fig"}). The K27M in *H3F3A* is a major mutation found in diffuse midline gliomas \[[@b22-jptm-2017-03-08]-[@b25-jptm-2017-03-08]\]. Additionally, a *C11orf95-RELA* fusion was found in supratentorial ependymomas \[[@b26-jptm-2017-03-08]-[@b34-jptm-2017-03-08]\]. A V600E mutation in *BRAF* was found in circumscribed gliomas, such as pleomorphic xanthoastrocytoma (PXA) (66%) \[[@b35-jptm-2017-03-08]-[@b38-jptm-2017-03-08]\], gangliogliomas (25%) \[[@b35-jptm-2017-03-08],[@b38-jptm-2017-03-08]\], and pilocytic astrocytomas (15%) \[[@b35-jptm-2017-03-08],[@b38-jptm-2017-03-08]\]. Furthermore, a *BRAF-TIAA1549* fusion was discovered in pilocytic astrocytoma (more than 70%) ([Fig. 2](#f2-jptm-2017-03-08){ref-type="fig"}) \[[@b39-jptm-2017-03-08]-[@b43-jptm-2017-03-08]\]. **SMARCB1* (INI1)* or **SMARCA4* (BRG1)* gene mutations or deletions were observed in atypical teratoid/rhabdoid tumors (AT/RT) \[[@b44-jptm-2017-03-08]-[@b46-jptm-2017-03-08]\], and a *NAB2-STAT6* fusion was present in solitary fibrous tumor/hemangiopericytomas \[[@b47-jptm-2017-03-08]-[@b49-jptm-2017-03-08]\]. Meningiomas also have typical gene mutations according to the tumor type and grade. Sixty percent of the sporadic meningiomas have mutations in *TRAF7*, *KLF4*, *AKT1*, *SMO*, and *PIK3CA* \[[@b50-jptm-2017-03-08]-[@b52-jptm-2017-03-08]\]. Among them, mutations in *TRAF7* and *KLF4* are found in secretory-type meningiomas and mutations in *TRAF7*/*AKT1*/*PIK3CA* are found in meningothelial and transitional-type meningiomas \[[@b52-jptm-2017-03-08],[@b53-jptm-2017-03-08]\]. Mutations in *TRAF7* are the most common genomic aberrations and are found in 12%--15% of sporadic meningiomas, preferentially fibrous and transitional subtype, which are found concurrently with mutations in *KLF4*, *AKT1*, or *PIK3CA*, but are mutually exclusive with mutations in *SMO* and neurofibromatosis type 2 (*NF2*) \[[@b53-jptm-2017-03-08]\]. *NF2*-associated meningiomas have mutations in *NF2*. Atypical and anaplastic meningiomas usually have mutations in *TERTp* or marked copy number aberrations and loss of **CDKN2A*/2B* \[[@b53-jptm-2017-03-08]\]. These findings demonstrate that tumors are genetic disorders and that certain mutations can represent different biological behaviors and result in different prognoses.

Molecular testing, such as molecular profiling of brain tumors, improves diagnostic accuracy, allows for predictive prognosis, and enables target identification. At present, target therapy has become one of the most promising treatment options for many tumors. Here, we summarize and provide guidelines for the molecular testing of brain tumors. High-throughput genomic studies, such as next-generation sequencing (NGS), can be useful financially and practically by rapidly replacing time-consuming and labor-intensive conventional methods since multiple molecular genetic abnormalities must be studied in order to diagnose various brain tumors.

IMPORTANT MOLECULAR GENETICS FOUND IN BRAIN TUMORS
==================================================

The indications and methods of each genetic study common to brain tumors are summarized in [Tables 1](#t1-jptm-2017-03-08){ref-type="table"}--[6](#t6-jptm-2017-03-08){ref-type="table"}. Integration of morphological criteria and genetic alterations is the guideline for an accurate diagnosis, risk classification, and development of therapeutic strategies.

Mutations in *IDH1/2*
---------------------

The discovery of mutations affecting the enzymatic function of IDH in gliomas provided a fundamentally new insight into the biology of gliomagenesis and triggered molecular classification of gliomas by a somatic mutation. IDH catalyzes the oxidative decarboxylation of isocitrate to produce α-ketoglutarate (α-KG) and CO~2~, but mutant *IDH1/2* has a preferential affinity for α-KG instead of isocitrate outside of the citric acid cycle, thus leading to the production and accumulation of the oncometabolite 2-hydroxyglutarate (2HG) \[[@b67-jptm-2017-03-08]-[@b70-jptm-2017-03-08]\]. Dang *et al*. \[[@b68-jptm-2017-03-08]\] hypothesized that 2HG induces redox stress due to damage to the respiratory chain, which subsequently promotes the mutagenesis and development of gliomas. The α-KG--dependent prolyl hydroxylases modulate HIF1α levels and changes in the HIF1α downstream pathway, leading to an increase in reactive oxygen species levels and potentially contributing to the risk of cancer \[[@b71-jptm-2017-03-08]\].

The glioma-CpG island methylator phenotype (G-CIMP) subset is distinctively and invariably found in the gliomas with mutant *IDH*, which is the proneural transcriptional group \[[@b72-jptm-2017-03-08]\]. 2HG, the oncometabolite produced by mutant *IDH1/2*, inhibits α-KG--dependent dioxygenases including histone demethylases and the Ten-Eleven Translocation (*TET*) family of histone 5-methylcytosine hydroxylase, which directly induce the hypermethylated state \[[@b73-jptm-2017-03-08]\]. The G-CIMP subgroup of GBMs is common in younger patients and has a longer lifespan \[[@b13-jptm-2017-03-08],[@b17-jptm-2017-03-08],[@b30-jptm-2017-03-08],[@b67-jptm-2017-03-08],[@b74-jptm-2017-03-08]-[@b76-jptm-2017-03-08]\].

All *IDH1/2* mutations are common in 70%--80% of type II and III infiltrating gliomas and are found in 100% of oligoden-drogliomas and IDH-mutant GBMs \[[@b67-jptm-2017-03-08]\].

### TP53 mutation

*TP53* is a typical tumor suppressor gene located in 17p13.1, which encodes the nuclear protein p53. The p53 protein responds to diverse cellular stresses to regulate the expression of its target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or metabolic changes. Mutated *TP53* genes and overexpressed abnormal p53 protein, which has a longer half-life than wild type p53, are associated with a variety of human cancers, including Li-Fraumeni syndrome and many hereditary gliomas. As mentioned in the introduction, the p53 signaling pathway is one of the major abrogated pathways of astrocytic tumors including GBMs. WHO class II and III astrocytic tumors show high levels of *TP53* mutations (94%) and/or p53 overexpression ([Tables 3](#t3-jptm-2017-03-08){ref-type="table"}, [4](#t4-jptm-2017-03-08){ref-type="table"}) \[[@b3-jptm-2017-03-08]\]. However, these alterations are rare in oligodendrogliomas, well-circumscribed astrocytic tumors including pilocytic astrocytomas, pleomorphic xanthoastrocytomas, and subependymal giant cell astrocytomas, ependymomas, and embryonal tumors such as medulloblastoma, except for the SHH-type, p53-activated subgroup.

*ATRX* is an X-linked gene of α-thalassemia and mental retardation syndrome
---------------------------------------------------------------------------

*ATRX* is located in Xq21.1, encodes a 280-kDa nuclear protein, and has been shown to be involved in a wide range of cellular functions such as DNA recombination, repair, and transcription regulation \[[@b82-jptm-2017-03-08]\]. It binds strongly within the promyelocytic leukemia body of the nucleus. When *ATRX* interacts with *DAXX*, this complex functions as a histone chaperone complex for the deposition of histone variant H3.3 into heterochromatic repeats including pericentric, telomeric, and ribosomal DNA repeat sequences \[[@b83-jptm-2017-03-08]\]. Functional mutations of this gene have been associated with sister chromatid clumps and defects, abnormal DNA methylation, and the maintenance of telomerase-independent telomeres, resulting in an alternative lengthening of telomeres (ALT). Decreased nuclear expression of ATRX and *ATRX* mutations are observed in grade 2 and 3 astrocytic tumors including *IDH* mutant gliomas (86%), IDH-mutant GBMs (85%), and pediatric high grade gliomas such as diffuse midline gliomas (DMGs) ([Figs. 1](#f1-jptm-2017-03-08){ref-type="fig"}, [2](#f2-jptm-2017-03-08){ref-type="fig"}) \[[@b3-jptm-2017-03-08]\].

Histone *H3F3A* (K27M, K36, and G34) mutations
----------------------------------------------

Histone protein H3.1 and H3.2 are expressed only in the S phase and are integrated into the chromatin by chaperone CAF1 during DNA replication only, but H3.3 is expressed at all stages of the cell cycle and can be integrated into the chromatin independently of DNA replication. H3.3 is associated with active chromatin such as H3K4 trimethylation, which promotes open chromatin structure for the binding of co-factors and transcription factors to activate transcription \[[@b85-jptm-2017-03-08]\]. Recurrent mutations in *H3F3A*, which encodes the replication-independent histone 3 variant H3.3, were first detected in the pediatric diffuse infiltrating pontine glioma (DIPG) by a comprehensive WES analysis. DIPG was later renamed as DMG and is considered a H3 K27M mutation in the new 2016 WHO classification ([Fig. 2](#f2-jptm-2017-03-08){ref-type="fig"}) \[[@b7-jptm-2017-03-08],[@b23-jptm-2017-03-08]\]. Eighty percent of pontine gliomas (DIPG) and 70% of other loci DMGs contain a mutation in one allele of the *H3F3A* gene, which is a mutation on the histone tail (K27M, K36, G34R/G34V), an important post-translational modification factor \[[@b25-jptm-2017-03-08]\].

The histone *H3F3A* mutant gliomas have a poor prognosis regardless of histopathological grade. K27M-H3.3 mutations occur mainy in young patients (median age, 11 years) and G34R/V-H3.3 mutations occur in older children and young adults (median age, 20 years \[[@b22-jptm-2017-03-08]\]. All of the cases with G34-H3.3 mutations are in pediatric GBMs (13/13), and especially associated with mutations in *ATRX* and *DAXX* \[[@b22-jptm-2017-03-08]\]. Loss of ATRX is associated with the ALT phenotype; thus, ALT often coexists with mutations in *ATRX/H3F3A/TP53* \[[@b22-jptm-2017-03-08]\].

Codeletion of chromosome 1p/19q and mutations in *CIC* and *FUBP1*
------------------------------------------------------------------

Simultaneous deletion of chromosome 1p/19q is a characteristic and early genetic event in oligodendroglial tumors, which is associated with better prognosis and is also a good indicator of the patient response to specific combination chemotherapy of procarbazine, lomustine, and vincristine (PCV). Recurrent mutations in *CIC* and *FUBP1* were found in 46%--53% and 15%--24% of oligodendrogliomas, respectively, in addition to a codeletion in 1p/19q and mutations in *IDH1* or *IDH2* ([Fig. 1](#f1-jptm-2017-03-08){ref-type="fig"}) \[[@b86-jptm-2017-03-08]-[@b88-jptm-2017-03-08]\].

*FUBP1* is located in 1p31.1, and mutations in *FUBP1* are predicted to disrupt FUBP1 protein function ([Table 1](#t1-jptm-2017-03-08){ref-type="table"}). FUBP1 acts as an RNA binding protein and alterations of its normal function can lead to tumorigenesis, which has been suggested to act either as a protooncogene or a tumor suppressor gene depending on the tumor type \[[@b36-jptm-2017-03-08],[@b87-jptm-2017-03-08]\]. Through the c-Myc pathway, *FUBP1* promotes cell migration and protects cells from apoptosis.

The *CIC* gene on chromosome 19q13.2 represses genes induced by RTK pathway activation \[[@b89-jptm-2017-03-08]\]. Although the function of human CIC protein is not known, a recent study in cultured cells demonstrated that CIC acts together with IDH1 to regulate citrate levels in the cytoplasm. *CIC* mutations promote the accumulation of 2HG and reduce clonogenicity in the setting of *IDH1* mutations. Loss of 19q in oligodendroglial tumors unmasks mutations in the *CIC* gene \[[@b87-jptm-2017-03-08],[@b90-jptm-2017-03-08]\]. In this regard, the co-existence of *IDH1* with *CIC* or *FUBP1* mutations may partially explain the slower tumor growth and longer survival of oligodendrogliomas with mutations in *IDH1* and a codeletion of 1p/19q when compared to other diffuse gliomas \[[@b90-jptm-2017-03-08]\]. The overall survival rate of patients with oligodendrogliomas with *CIC* mutations was lower than that of patients without *CIC* mutations, and the *FUBP1* mutation was significantly associated with unfavorable progression-free survival \[[@b15-jptm-2017-03-08]\]. However, oligodendrogliomas cannot be diagnosed with *CIC* or *FUBP1* mutations only \[[@b15-jptm-2017-03-08]\].

*EGFR* amplification and *EGFRvIII* truncation mutations
--------------------------------------------------------

*EGFR*, also called *Erb1* or *HER1*, is located on chromosome 7q12 and acts as an *ErbB* family receptor tyrosine kinase. *EGFR* amplification is closely related to EGFR overexpression. *EGFRvIII*-positive tumor cells exhibit particularly high levels of *mTOR* signal and exhibit the most proliferative and aggressive phenotype similar to GBMs ([Fig. 1](#f1-jptm-2017-03-08){ref-type="fig"}). The *EGFRvIII* mutation is a 801 bp frame deletion from exons 2 to 7 of the *EGFR* gene, which is associated with *EGFR* amplification and the response to antibody therapy as well as poor prognosis \[[@b93-jptm-2017-03-08]\]. In addition to *EGFR* amplification, *EGFRvIII*-positive GBM cell lines are sensitively suppressed by first-generation *EGFR* inhibitors (erlotinib, gefitinib, vandetanib) and second-generation *EGFR* inhibitors (NT113) as compared to GBM cell lines in which *PTEN* tumor suppressor genes are lost *in vitro* \[[@b94-jptm-2017-03-08]\].

EGFR immunohistochemistry is usually uniform in tumors expressing high levels of the protein, however, EGFRvIII staining is heterogeneous and usually present in only a subset of tumor cells. Therefore, representative sampling of tumor tissue is important to avoid false-negative results \[[@b56-jptm-2017-03-08],[@b57-jptm-2017-03-08]\].

Unlike *EGFR* point mutations, *EGFR* fusions with *SEPT14*, *PSPH*, or *SEC61G* has also been shown to play a role in GBMs, offering a unique opportunity to investigate fused oncogene dependencies \[[@b94-jptm-2017-03-08]\].

Deletions in **CDKN2A*/2B*
--------------------------

**CDKN2A*/2B* is a tumor suppressor gene located on chromosome 9p21.3, because it encodes a cyclin-dependent kinase inhibitor (p16) and is a cell cycle regulator of the *Rb* pathway. In 60% of GBMs and 11% of low-grade gliomas including oligodendroglioma, pleomorphic xanthoastrocytoma, and pilocytic astrocytoma, the loss or inactivation of p16 protein as a result of a homozygous deletion or promoter methylation of **CDKN2A*/2B* is observed ([Fig. 1](#f1-jptm-2017-03-08){ref-type="fig"}) \[[@b55-jptm-2017-03-08]\]. It is also one of the more commonly altered genes in PXA and high grade gliomas in both adults and children ([Fig. 2](#f2-jptm-2017-03-08){ref-type="fig"}) \[[@b35-jptm-2017-03-08],[@b95-jptm-2017-03-08]\]. After adjusting for the *IDH* mutational status, sex, and age, *CDKN2A* deletions were strongly associated with poorer overall survival in astrocytomas but not in oligodendrogliomas \[[@b18-jptm-2017-03-08]\].

*BRAF* mutations and *BRAF-*KIAA1549** fusions
----------------------------------------------

*BRAF* V600E mutations and fusions of *BRAF* with *KIAA1549* or *FAM131B* are characteristics of pilocytic astrocytomas. In 2008, a tandem duplication was confirmed in 7q34, and a new fusion gene was found to be generated by a fusion between the *KIAA1549* gene and *BRAF* genes, which was previously uncharacterized in pilocytic astrocytomas \[[@b58-jptm-2017-03-08]\]. Fusions between *KIAA1549* exon 15 and *BRAF* exon 9 and those between *FAM131B* exon 2 and *BRAF* exon 9 are derived from a 2.0 Mb tandem duplication in chromosome band 7q34, which can be detected by realtime polymerase chain reaction (PCR) or fluorescent *in situ* hybridization (FISH) ([Fig. 2](#f2-jptm-2017-03-08){ref-type="fig"}) \[[@b62-jptm-2017-03-08]\].

The *BRAF* V600E mutation was found in two-thirds of all pleomorphic xanthoastrocytomas, one-fourth of gangliogliomas, and one-seventh of pilocytic astrocytomas \[[@b35-jptm-2017-03-08]\].

In children, *CDKN2A* deletions and *BRAF* mutations are early events in low-grade gliomas (pediatric low-grade glioma \[PLGG\]) undergoing malignant transformation ([Fig. 2](#f2-jptm-2017-03-08){ref-type="fig"}) \[[@b96-jptm-2017-03-08]\]. The *BRAF* V600E mutant PLGG has longer transformation latency periods than the *BRAF* wild type PLGG (median latency period, 6.65 years vs 1.59 years, respectively) \[[@b96-jptm-2017-03-08]\]. As a result, all of the patients with secondary high-grade glioma (sHGGs) containing mutant *BRAF* were diagnosed at age 9 or older \[[@b96-jptm-2017-03-08]\]. The sHGG in children showed recurrent changes of *BRAF* V600E mutations and *CDKN2A* deletions in 39% and 57%, respectively.

*TERTp* mutations
-----------------

Human telomerase is a ribonucleoprotein that regulates the length of telomeric DNA at the ends of chromosomes; therefore, it plays an important role in cellular immortalization and oncogenesis \[[@b13-jptm-2017-03-08]\]. Mutations in *TERTp* are molecular hallmarks of glioma, occurring in more than 80%--96% of IDH-wildtype GBMs and oligodendrogliomas, but less frequently present in grade II and III astrocytomas (38.5%) ([Table 1](#t1-jptm-2017-03-08){ref-type="table"}, [Fig. 1](#f1-jptm-2017-03-08){ref-type="fig"}) \[[@b97-jptm-2017-03-08]\]. Chan *et al*. (2015) \[[@b98-jptm-2017-03-08]\] found that mutations in *TERTp* are present in 41 of 142 (28.9%) grade II gliomas and 20 of 72 (27.8%) grade III gliomas. The mutations were always found in two hotspots (chr5: 1 295 228 C \> T and 1 295 250 C \> T), resulting in a somatic gain-of-function mutation and an enhancement of *TERTp* activity \[[@b99-jptm-2017-03-08]\]. A relative telomere length is strongly correlated with *TERTp* mutations. These two hot spot mutations are mutually exclusive in gliomas and *TP53* mutations, but coincident with a 1p/19q codeletion \[[@b100-jptm-2017-03-08]\].

The prognostic effect of the *TERTp* mutation is controversial. Some studies have suggested that *TERTp* mutations in low-grade gliomas are associated with shorter progression-free survival \[[@b101-jptm-2017-03-08]\]. Other researchers have found that *TERTp* mutations are a predictor of a poorer response to temozolomide \[[@b102-jptm-2017-03-08]\]. *TERTp* mutations are associated with good outcome in gliomas with mutant *IDH*, but it is also related to poor outcome in gliomas with wild type *IDH* \[[@b97-jptm-2017-03-08]\]. In gliomas with wildtype *IDH* or GBMs with hypomethylated **MGMT**, *TERTp* mutations were found to predict poor prognosis \[[@b103-jptm-2017-03-08]\]. Therefore, when using the *TERTp* mutational status as a prognostic factor, other factors such as mutations in *IDH* and tumor grade should be considered \[[@b101-jptm-2017-03-08]\]. Primer sequences for *TERTp* mutation is summarized in [Table 5](#t5-jptm-2017-03-08){ref-type="table"}.

*C11orf95-RELA* fusion
----------------------

More than two-thirds of supratentorial ependymomas contain oncogenic fusions between *RELA* (the principle effector of canonical nuclear factor κB \[NF-κB\] signaling) and *C11orf95* (an uncharacterized gene) ([Table 2](#t2-jptm-2017-03-08){ref-type="table"}) \[[@b32-jptm-2017-03-08],[@b34-jptm-2017-03-08]\]. Ependymomas carrying the *C11orf95-RELA* fusion are characterized by a nuclear accumulation of p65RelA (*NFκB*) indicating a pathological activation of the *NFkB* signaling pathway \[[@b34-jptm-2017-03-08]\]. *C11orf95-RELA* fusions result from chromothripsis involving chromosome 11q13.1. Furthermore, the *C11orf95-RELA* fusion protein was found to spontaneously translocate to the nucleus to activate NF-kB target genes, and to rapidly transform neural stem cells, the cell of origin for ependymomas, to form these tumors in mice, which is a poor prognostic marker ([Table 2](#t2-jptm-2017-03-08){ref-type="table"}) \[[@b34-jptm-2017-03-08]\].

*CTNNB1* mutations
------------------

Mutations in *CTNNB1* on chromosome 3p21, which encodes β-catenin, promote the stabilization and nuclear translocation of itself, therefore activating the WNT signaling pathway ([Table 2](#t2-jptm-2017-03-08){ref-type="table"}). The nuclear translocation of β-catenin is present in medulloblastomas, solitary fibrous tumors/hemangiopericytomas, and adamantinomatous-type craniopharyngiomas. Nuclear expression of β-catenin is always focal. Overall, these mutations can act as future therapeutic targets in nuclear β-catenin--positive tumors.

*MYC* and *MYCN* amplification
------------------------------

*MYC* is a regulator gene that encodes for transcription factors for c-myc, Mycn, and Mycl \[[@b77-jptm-2017-03-08]\]. Nuclear myc protein has multiple functions such as cell cycle progression, apoptosis, and cellular transformation. *MYC/MYCN* amplification or overexpression is found not only in type-3 medulloblastomas, but also in other aggressive subtypes of medulloblastomas, which account for approximately 10% of medulloblastomas \[[@b78-jptm-2017-03-08],[@b104-jptm-2017-03-08]\].

*SMARCB1* and *SMARCA4* mutations
---------------------------------

AT/RT are highly malignant CNS embryonal tumors with rhabdoid morphology, where biallelic inactivation of *SMARCB1* results in a loss of INI1 (BAF47) nuclear expression ([Tables 2](#t2-jptm-2017-03-08){ref-type="table"}--[4](#t4-jptm-2017-03-08){ref-type="table"}). The loss of BRG1 nuclear expression in AT/RT with mutations in *SMARCA4* is rarely reported \[[@b105-jptm-2017-03-08]\]. The tumor suppressors *SMARCB1* and *SMARCA4* are located on 22q11.23 and 19p13.2, respectively.

The biallelic loss of *SMARCB1* and *SMARCA4* can be recognized by nuclear negativity of the INI1 and BRG1 immunostaining. However, FISH and DNA sequencing can also be used to detect these genetic alterations.

WES and RNA sequencing of AT/RT revealed few somatic mutations and several deregulated signaling pathways related to the *SMARCB1* deficiency \[[@b106-jptm-2017-03-08]\].

*C19MC* amplification
---------------------

Chromosomal 19 micro-ribosomal clusters (*C19MC*), localized at 19q13.42, are produced by chromothripsis, a phenomenon of chromosomal breakage and inaccurate recombination, resulting in the rearrangement of thousands of clustered chromosomes in a single event to a localized and restricted genomic region on one or more chromosomes \[[@b107-jptm-2017-03-08]\]. *C19MC* amplification is a genetic feature of embryonal tumors with multilayer rosettes (ETMR), supratentorial ependymomas, and medulloepitheliomas ([Table 2](#t2-jptm-2017-03-08){ref-type="table"}) \[[@b108-jptm-2017-03-08]\]. This abnormality can be detected by FISH.

*MGMT* promoter hypermethylation
--------------------------------

One of the most clinically important DNA methylation markers in GBMs is the promoter of *MGMT*, a DNA repair enzyme that can abrogate the effects of alkylating chemotherapy such as temozolomide. More than 50% of oligodendrogliomas and 30%--40% of adult high-grade gliomas (approximately 40% of IDH-wildtype GBMs) reveal *MGMT* methylation. *MGMT* promoter hypermethylation induces gene silencing and susceptibility to combined temozolomide and radiation therapy. In cases of oligodendroglioma with promoter methylation of the *MGMT* gene, whether or not PCV chemotherapy is advantageous remains controversial \[[@b59-jptm-2017-03-08]\]. However, it is still considered to be the most accurate predictive factor for survival during PCV chemotherapy \[[@b60-jptm-2017-03-08]\].

METHODS OF MOLECULAR TESTING
============================

The molecular testing methods commonly used in pathology laboratories include immunohistochemical staining, direct sequencing, FISH, chromosomal genomic hybridization, and NGS.

Immunohistochemical studies
---------------------------

Some of the genetic changes can be detected by immunohistochemical studies. *IDH* R132H, H3 K27M, *BRAF* V600E, and *EGFRvIII* can be diagnosed using mutation-specific monoclonal antibodies (mAbs). *IDH1* (H09), K27M, and *BRAF* VE1 antibodies have 100% sensitivity and specificity to detect gene mutations \[[@b36-jptm-2017-03-08]\]. The INI-1 (*SMARCB1*), BRG1 (*SMARCA4*), p16 (*CDKN2A*), *CIC*, and *FUBP1* mutations and *MGMT* methylation can be detected by the loss of expression. *TP53* mutations are detected by the complete loss of expression or overexpression via the stabilization of the mutant protein. In addition, *STAT6* (*NAB2-STAT6* fusion), *L1CAM* (protein marker for *RELA-c9ORF95* fusion), and the amplifications of *EGFR*, *MET*, and *PDGFR* can be analyzed by overexpression assays ([Table 4](#t4-jptm-2017-03-08){ref-type="table"}) \[[@b21-jptm-2017-03-08],[@b24-jptm-2017-03-08],[@b36-jptm-2017-03-08],[@b55-jptm-2017-03-08]\]. Mutations in several genes give rise to the overexpression or loss of proteins, depending on whether the mutation is a gain of function or a loss of function mutation, respectively. For example, p53 nuclear overexpression reflects a *TP53* mutation, and p16 nuclear and cytoplasmic losses are associated with a *CDKN2A* homozygous deletion. Furthermore, the nuclear loss of *ATRX* is associated with an *ATRX* mutation, and MLH1, MSH2, and PMS nuclear losses are associated with methylation of these genes. Among these, all but *TP53* have high correlations between immunohistochemical results and molecular genetic studies. The correlation rate of p53 between immunohistochemistry and mutation studies is low. This is because p53 immunoreactivity may have resulted from the prolongation of half-life either due to p53 mutations or the accumulation of wild type protein brought about by mechanisms other than those caused by mutations, such as a complex formation with MDM2 overexpression products \[[@b109-jptm-2017-03-08]\], whereas p53 negativity can be observed by the methylation of the *TP53* promoter. Therefore, overexpression of p53 protein is not always associated with mutations in conserved exons of the p53 gene.

Direct sequencing
-----------------

The rapidly growing number of prognostic and predictive genetic markers in neuro-oncology has led to an increasing need for a more thorough molecular analysis of brain tumor specimens in a modern pathology setting. Although several diagnostically important mutations can be detected by immunohistochemistry, this is not the case for the full spectrum of alterations now known to be of relevance. Therefore, the mutations of *IDH 1/2*, *BRAF*, *CTNNB1*, *H3F3A* (K27M, G34), *TP53*, *ATRX*, and *TERTp* are usually detected by direct sequencing. The sequencing conditions, primer sequences, and PCR product sizes that are currently being used for brain tumor diagnosis are summarized in [Table 5](#t5-jptm-2017-03-08){ref-type="table"}.

In order to detect mutations in *CIC* (missense mutations or small in-frame deletions) and *FUBP1* (indel, splicing alteration, and nonsense mutations) in the functional regions such as the HMG box and CI motif, NGS is required because the mutation sites of these two genes are widely distributed along the coding regions \[[@b88-jptm-2017-03-08]\].

Sanger sequencing is a method of DNA sequencing based on the selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during DNA replication *in vitro*, which was developed by Frederick Sanger and colleagues in 1977 \[[@b91-jptm-2017-03-08]\].

Recently, one-step Sanger sequencing (combining the amplification and sequencing steps) methods such as Ampliseq and SeqSharp have been developed that allows for rapid sequencing of target genes without cloning or prior amplification.

However, covering all potentially clinically relevant genes in a routine diagnostic setting by these methods has become virtually impossible. Reliable high-throughput methods allowing for parallel analysis of multiple targets emerged as an attractive alternative for comprehensive diagnostic neuropathology. NGS provides opportunities to evaluate many genomic targets with high accuracy and sensitivity due to high sequencing coverage. However, the Sanger method is widely used for small-scale projects, and validation of NGS results, especially long serial DNA sequence reads that are greater than 500 nucleotides.

Pyrosequencing
--------------

Pyrosequencing is a method of DNA sequencing based on the "sequencing by synthesis" principle \[[@b110-jptm-2017-03-08]\]. It differs from Sanger sequencing in that it relies on the detection of pyrophosphates that are released upon nucleotide incorporation rather than chain termination with dideoxynucleotides. Various gene alterations can be detected by pyrosequencing, including *IDH1/IDH2* mutations, *TERTp* mutation and *MGMT* methylation \[[@b92-jptm-2017-03-08],[@b111-jptm-2017-03-08]-[@b113-jptm-2017-03-08]\].

NGS
---

More recently, high volume Sanger sequencing has been supplanted by NGS methods, especially for large-scale, automated genome analyses. NGS is a high-capacity parallel sequencing process that handles hundreds to millions of DNA fragments simultaneously \[[@b114-jptm-2017-03-08],[@b115-jptm-2017-03-08]\]. Currently, there are second- and third-generation sequencing technologies that continue to reduce the cost of DNA sequencing and improve accuracy. The ability to multiplex several samples also leads to increased throughput and reduced cost. Soon, NGS will enter clinical practices but it is still uncertain whether it can replace the established techniques. Depending on the type of NGS panel, it can only detect single nucleotide variations and indels or embrace CNV and translocations. The performance of the NGS panel requires rigorous validations and strict quality control for its sensitivity, specificity, and accuracy. There are several NGS panels for brain tumor companion diagnosis \[[@b78-jptm-2017-03-08],[@b79-jptm-2017-03-08],[@b95-jptm-2017-03-08],[@b116-jptm-2017-03-08]\]. Current practice and guidelines for the clinical use of a NGS-based oncology test are described in Strom's 2016 paper \[[@b117-jptm-2017-03-08]\]. A comparison of different NGS-based diagnostic tools is summarized in Lapin *et al*. paper (2016) \[[@b118-jptm-2017-03-08]\].

FISH
----

FISH studies can be easily used to identify chromosomal aberrations, such as a 1p/19q codeletion, *EGFR* amplification or high polysomy, *PTEN* and *CDKN2A* homozygous or hemizygous deletions, *C-MYC* and *N-MYC* amplifications, *BRAF* fusions or copy gains, *C11orf95-RELA* fusions, *C11orf95-YAP1* fusions, *YAP1-MAMLD1* fusions, and *MYB-QKI* fusions. The probes and reading criteria of currently used FISH for the diagnosis and prognosis of brain tumors are summarized in [Table 6](#t6-jptm-2017-03-08){ref-type="table"}.

The presence or absence of the 1p/19q codeletion can be determined by FISH, comparative genomic hybridization (CGH), or microsatellite analyses for a loss of heterozygosity (LOH) on chromosomes 1p and 19q \[[@b119-jptm-2017-03-08],[@b120-jptm-2017-03-08]\].

When the amount of DNA is insufficient to carry out the single nucleotide polymorphism or CGH array, microsatellite analysis is performed to evaluate via PCR to determine whether there is a LOH of chromosome 1p and 19q \[[@b121-jptm-2017-03-08]\]. In cases of 1p/19q codeletion, the evaluation and interpretation of FISH results are based on International Society of Pediatric Oncology (SIOP) guidelines for neuroblastoma study \[[@b80-jptm-2017-03-08]\]. For each hybridization, the number of green and orange signals is assessed for a minimum of 100 nonoverlapping nuclei. An interpretation of a deletion was made when \> 50% of nuclei harbored less than a single orange signal (0/2, 1/2, 0/3, 1/3, etc). Such deletions most likely correspond to a LOH ([Fig. 3](#f3-jptm-2017-03-08){ref-type="fig"}). However, with increasing grades of malignancy, genomic polyploidies may be encountered. These chromosomal polysomies may be balanced (e.g., 3/3, 4/4, 5/5, etc.) or imbalanced (e.g., 3/2, 4/2, 3/5, 4/5, etc.), indicating relative gains or losses. Whether an imbalance situation with relative loss of the target 1p or 19q corresponds to a hemizygous deletion in the presence of reduplication cannot be solved by FISH. In such cases, secondary assays such as PCR-based LOH or CGH studies should be used for better specificity \[[@b80-jptm-2017-03-08]\].

Methylation specific PCR (O6 methyl guanine methyl transferase)
---------------------------------------------------------------

Methylation can be detected by methylation specific PCR (MSP), pyrosequencing, multiplex ligation-dependent probe assay, or BeadChip microarray \[[@b57-jptm-2017-03-08],[@b113-jptm-2017-03-08],[@b122-jptm-2017-03-08]\]. In the Seoul National University Hospital, MSP is conducted using an EZ DNA methylation Kit (catalog No. D5005, Zymo Research, Irvine, CA, USA) to determine the methylation status of the *MGMT* promoter. The primer set is described in [Table 5](#t5-jptm-2017-03-08){ref-type="table"}. The primer sequences for MGMT were as follows: methylated forward, 5′-TTT CGA CGT TCG TAG GTT TTC GC-3′; methylated reverse, 5′-GCA CTC TTC CGA AAA CGA AACG 3′; unmethylated forward, 5′-TTT GTG TTT TGA TGT TTG TAG GTT TTT GT-3′; and unmethylated reverse, 5′-AAC TCC ACA CTC TTC CAA AAA CAA AAC A-3′.

DISCUSSION
==========

Among primary adult and pediatric CNS tumors, diffuse gliomas are the largest and most diverse group. They usually arise in the cerebral hemispheres and are defined by their widely infiltrative properties and tendency for biological progression. According to the 2016 WHO criteria, gliomas can be classified using combined histological and molecular markers as diffuse astrocytic and oligodendroglial tumors, other astrocytic tumors, ependymal tumors, or other gliomas. The most aggressive astrocytic tumors with a dismal prognosis are the GBMs with wild type IDH and DMG, histone-mutant (H3 K27, G34, and K36). Less infiltrative gliomas in children and young adults include WHO grade I pilocytic astrocytomas,WHO grade II/III pleomorphic xanthoastrocytomas, and WHO grade I subependymal giant cell astrocytomas. Other major classes of CNS tumors include neuronal and mixed glioneuronal tumors as well as embryonal tumors such as cerebellar medulloblastomas, and AT/RT, and extra-axial meningiomas.

The diagnosis of CNS tumors is historically primarily based on histopathological features. However, studies have shown that patients with morphologically identical tumors have different clinical outcomes and treatment responses due to the different molecular genetic characteristics of the tumor. Therefore, many molecular markers became deeply integrated into the diagnosis of CNS tumors and are now used to guide prognosis and treatment of patients. If molecular genetic testing is not possible, a diagnosis is made with the nonspecific term "glioma, not otherwise specified (NOS)." In this case, because the grade and the exact diagnosis of the tumor as well as the biological markers are covered, the precision diagnosis and the appropriate treatments are no longer possible. These "NOS diagnostics" must be reclassified using molecular genetic diagnostic tools.

Diffuse astrocytic and oligodendroglial tumors
----------------------------------------------

Molecular genetic testing can classify diffuse astrocytic and oligodendroglial tumors (WHO grades II--III) and differentiate IDH-mutant GBMs from IDH-wildtype GBMs based on molecular signature of astrocytic and oligodendrogial tumors. Diffuse astrocytic tumors and IDH-mutant GBMs are characterized by mutations in *IDH1/2*, *TP53*, and *ATRX*, whereas oligodendrogliomas are characterized by mutations in *IDH1/2*, *CIC*, *FUBP1*, and *TERTp*, and a codeletion in 1p/19q (whole chromosomal arm deletion) ([Fig. 1](#f1-jptm-2017-03-08){ref-type="fig"}). IDH-wildtype GBMs can be identified by demonstrating a dysregulation of several critical signaling pathways and a lack of the above-mentioned genetic alterations except *TERTp* mutations, which are common in IDH-wildtype GBM. The main signaling pathways involved in IDH-wildtype GBMs are RTK/RAS/PI3K pathways (via amplification and mutations in *EGFR* \[*EGFRvIII*\], *PIK3CA*, *RAS*, *NF1*, and *MET*) and *TP53* and *RB1* suppressor pathways (via mutations in or loss of *TP53*, *CDKN2A*, and RB1 genes) ([Fig. 1](#f1-jptm-2017-03-08){ref-type="fig"}) \[[@b94-jptm-2017-03-08]\].

Mutations in *IDH1/2* should be studied in diffuse gliomas for the WHO classification of CNS tumors. They are favorable prognostic markers and are genomic abnormalities initially present in both astrocytic and oligodendroglial tumors. Therefore, from the revised version of 2016 fourth edition of the CNS Tumor Classification, these two tumor categories have been combined as diffuse astrocytic and oligodendroglial tumors \[[@b7-jptm-2017-03-08]\]. *P53* and *ATRX* mutations are now the hallmark of WHO grade II and grade III astrocytic tumors. *TERTp* mutations, such as C228T and C250T, are found in more than 90% of oligodendroglial tumors and in more than 80% of GBMs as well as about 30%--40% of lower grade gliomas. Mutations in *TERTp* were associated with poor survival and resistance to radiotherapy in GBMs and in lower grade gliomas (grade II and III) without *IDH* mutation; however, *TERTp* mutations were associated with a favorable prognosis in lower grade gliomas with IDH mutations \[[@b63-jptm-2017-03-08],[@b123-jptm-2017-03-08]\].

High- and low-grade pediatric gliomas
-------------------------------------

Pediatric high-grade gliomas are unique, featuring mutations in *H3F3A*, *ATRX*, and *DAXX*, whereas PLGGs contain mutations or rearrangements in *BRAF*, *FGFR1*, or *MYB*. Furthermore, mutations in *IDH* are rare unless the patient is an adolescent ([Fig. 2](#f2-jptm-2017-03-08){ref-type="fig"}) \[[@b22-jptm-2017-03-08],[@b64-jptm-2017-03-08],[@b65-jptm-2017-03-08]\]. The circumscribed low-grade gliomas such as pilocytic astrocytoma, pilomyxoid astrocytoma, ganglioglioma, and PXA often harbor the *BRAF* V600E or *FGFR1* mutation, or gene fusions involving *BRAF* with *KIAA1549* or *FAM131B* \[[@b35-jptm-2017-03-08],[@b62-jptm-2017-03-08],[@b65-jptm-2017-03-08]\]. Histone H3 K27M, K36, and G34 mutations should be studied in pediatric glioma arising in the midline of CNS, i.e., the thalamus, pons, and spinal cord \[[@b124-jptm-2017-03-08]\]. However, the histone G34 mutation can be present in cerebral high-grade diffuse gliomas of the adult (about 5%) and the histone K36 mutation is rarely found in pediatric midline gliomas \[[@b84-jptm-2017-03-08]\].

Finally, the *BRAF* V600E mutation can be studied in low-grade glioneuronal tumors, such as PXA (about 60%), ganglioglioma (about 25%), pilocytic astrocytoma (about 15%), epithelioid GBM (about 50%), and papillary type of craniopharingioma (about 100%) \[[@b35-jptm-2017-03-08],[@b66-jptm-2017-03-08]\].

Medulloblastomas and other embryonic tumors
-------------------------------------------

Medulloblastomas have been recently divided into several subtypes based on specific driver mutations including *WNT*, *SHH*, group 3, and group 4 \[[@b125-jptm-2017-03-08]-[@b127-jptm-2017-03-08]\]. Mutations in *CTNNB1*, *DDX3X* or monosomy 6 in the Wnt pathway of medulloblastomas tend to lead to a much better prognosis. In contrast, *MYC* or *MYCN/CDK6* amplification is characteristic of group 3 and 4 medulloblastomas, which are far more likely to metastasize and have a poor prognosis even with intensive therapy. Tumors with *PTCH* and *SMO* belong to the *SHH* class, and have a relatively intermediate prognosis between *Wnt* and group 3/4 tumors. *CTNNB1* mutations can be present in classical-type medulloblastomas and adamantinomatous-type craniopharyngiomas \[[@b61-jptm-2017-03-08],[@b125-jptm-2017-03-08],[@b128-jptm-2017-03-08]\].

*SMARCB1* (*INI1*) or *SMARCA4* (*BRG1*) gene mutations or deletions are essential for the diagnosis of AT/RT, which show dismal prognosis \[[@b44-jptm-2017-03-08]-[@b46-jptm-2017-03-08]\]. The molecular genetic hallmark of ETMR is chromosome 19 miRNA cluster (*C19MC*) amplification \[[@b129-jptm-2017-03-08]\]. If certain tumors are morphologically similar to these tumors, i.e., rhabdoid feature, but molecular studies do not reveal these genetic abnormalities or molecular studies cannot be done, CNS embryonal tumor with rhabdoid feature or ETMR, NOS can be made as a pathological diagnosis \[[@b7-jptm-2017-03-08],[@b129-jptm-2017-03-08]\]. Therefore, the molecular characterization of medulloblastomas and embryonal tumors have lasting clinical value.

Meningioma and meningeal solitary fibrous tumor/hemangiopericytoma
------------------------------------------------------------------

Meningiomas often have mutations in the *NF2*, *AKT1*, *SMO*, and *KLF4* genes. Furthermore, meningiomas with mutant *NF2* are far more likely to exhibit atypical grade II features than the other subtypes \[[@b50-jptm-2017-03-08]-[@b52-jptm-2017-03-08]\]. Recurrent mutations in *KLF4*, *AKT1*, and *SMO* genes are often present in *NF2*-negative sporadic meningiomas \[[@b50-jptm-2017-03-08]\]. Clinical trials involving *SMO/AKT/NF2* inhibitors are open for patients with progressive meningiomas with *SMO/AKT/NF2* mutations \[[@b50-jptm-2017-03-08],[@b81-jptm-2017-03-08]\].

Meningeal hemangiopericytomas and solitary fibrous tumors have the same genetic modification as *NAB2-STAT6* gene fusion and are considered as the same tumor \[[@b48-jptm-2017-03-08]\]. This gene fusion study is essential for the differential diagnosis of histologically similar tumors.

Genetic alterations as prognostic and predictive markers and therapeutic targets
--------------------------------------------------------------------------------

Overall, the analysis of multiple molecular markers not only aids in establishing a correct morphological diagnosis, but also highlights the biological differences between morphologically similar tumors. It can also help with the clinical management of patients. For example, patients with *IDH1*/*TERTp*/*CIC*/*FUBP1* positive lower grade gliomas (WHO grades II--III) have a significantly longer median overall survival than those with *IDH1*/*TP53*/*ATRX* mutations \[[@b86-jptm-2017-03-08],[@b130-jptm-2017-03-08]\].

In addition, several molecular biomarkers showed promise in predicting responses to targeted therapies \[[@b94-jptm-2017-03-08],[@b131-jptm-2017-03-08]\]. For example, clinical trials are now open for GBMs with *EGFRvIII* mutations, vemurafenib is being evaluated in *BRAF* V600E mutant gliomas, and clinical response has already been observed in *FGFR3-TACC3*--positive patients treated with an *FGFR* inhibitor \[[@b78-jptm-2017-03-08]\]. NGS-based high-throughput molecular testing may provide potential new targets for precision medicine.

CONCLUSION
==========

We are now in the era of precision medicine, and have slowly caught up with the rapid development of precision medicine. High-throughput assays that can test multiple genes at once are essential for pathological diagnosis in daily practice, and NGS technology has made this possible. Current practices and guidelines for the clinical use of NGS-based oncology tests are well documented in Strom's paper \[[@b117-jptm-2017-03-08]\]. However, the medical insurance system has not kept up with the speed of technical development, the advances in diagnostic modalities, and newly developed treatment options. These are obstacles that prevents the doctors from implementing the precision medicine. In order to introduce the advanced knowledge and technologies into the daily practice of pathological diagnosis and clinical fields and reduce the costs, the medical insurance system should be formulated accordingly.
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![Schematic view of the classification of adult diffuse glioma according to the status of key genes.](jptm-2017-03-08f1){#f1-jptm-2017-03-08}

![Schematic view of the classification of pediatric diffuse gliomas according to the status of key genes. LG, low grade; HG, high grade; NOS, not otherwise specified. ^a^Characteristic but not required for diagnosis.](jptm-2017-03-08f2){#f2-jptm-2017-03-08}

![Schematic view, photographs, and reading criteria of the FISH probes for detecting 1p and 19q deletion. The FISH probes are long enough to find out the whole arm deletion. 1p/19q deleted cases show one orange signal and two green signals. The diagnostic cut-off of 1p and 10q deletion is written in the box. FISH, fluorescent *in situ* hybridization; LOH, loss of heterozygosity; CGH, comparative genomic hybridization; WES, whole exome sequencing.](jptm-2017-03-08f3){#f3-jptm-2017-03-08}

###### 

Mutation rate in various genes commonly mutated in brain tumors \[[@b3-jptm-2017-03-08],[@b41-jptm-2017-03-08],[@b55-jptm-2017-03-08]-[@b61-jptm-2017-03-08]\]

                                             WHO grade   Altered genes                               Genomic alteration (%)
  ------------------------------------------ ----------- ------------------------------------------- ----------------------------
  Astrocytoma                                II, III     *IDH* mutation                              65
                                                         *P53* mutation                              96
                                                         *ATRX* mutation                             96
  Glioblastoma                               IV          *EGFR* amplification                        57
                                                         *PDGFRA* amplification                      13
                                                         *EGFRvIII* mutation                         20
                                                         *PTEN* homozygous deletion                  25--35
                                                         *CDKN2A* homozygous deletion                61
                                                         *BRAF* V600E mutation                       1--2 (epithelioid GBM)
                                                         *TP53* mutation                             25--35
  Oligodendroglioma                          II, III     *IDH* mutation                              100
                                                         1p/19q codeletion                           100
                                                         *CIC/FUBP1* mutation                        56/29
                                                         *TERTp* mutation                            80--96
  Subependymal giant cell astrocytoma        I           *TSC1* and *TSC2* mutation                  100
  Pilocytic astrocytoma                      I           *BRAF-KIAA1549* fusion                      75 (cerebellar tumor)
                                                         *BRAF* V600E mutation                       13--15
  Pleomorphic xanthoastrocytoma              II, III     *BRAF* V600E mutation                       66
                                                         *CDKN2A* homozygous deletion                50
  Angiocentric glioma                        I           *MYB-QKI* fusion                            100
  Ganglioglioma                              I, III      *BRAF* V600E mutation                       25
                                                         *TSC1* and *TSC2* mutation                  Unknown
  Craniopharyngioma, papillary type          I           *BRAF* V600E mutation                       100
  Craniopharyngioma, adamantinomatous type   I           *CTNNB1* mutation                           100
  AT/RT                                      IV          *SMARCB1* deletion/mutation                 \> 95
                                             IV          *SMARCA4* mutation                          \< 5
  Cribriform tumor                                       *SMACB1* deletion/mutation                  100
  Meningioma, fibrous type                               *NF2* inactivation mutation (no hot spot)   45--55^50^
                                                         TRAF7/KLF4 mutation                         100 (secretory meningioma)
                                                         *AKT1* (p.Glu17Lys) mutation                2.5
                                                         *SMO* (p.Trp535Leu) mutation                5
                                                         *TERTp* mutation                            10
  Langerhans cell histiocytosis              I, III      *BRAF* V600E mutation                       50--57^54^

WHO, World Health Organization; GBM, glioblastoma; TSC, tuberous sclerosis complex; AT/RT, atypical teratoid/rhabdoid tumor.

###### 

Common pediatric molecular subgroups with molecular features \[[@b7-jptm-2017-03-08],[@b23-jptm-2017-03-08],[@b30-jptm-2017-03-08],[@b43-jptm-2017-03-08],[@b56-jptm-2017-03-08],[@b58-jptm-2017-03-08],[@b62-jptm-2017-03-08]-[@b66-jptm-2017-03-08]\]

  Tumor             Molecular subgroup                       Molecular feature                                                                                                                                                     Prognosis
  ----------------- ---------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  LGG               *BRAF*V600E                              70% of PXA, GG, DA                                                                                                                                                    Good
                    *KIAA-BRAF* fusion; *BRAF* duplication   90% of PA                                                                                                                                                             Good
                    *MYB-QKI* rearrangement                  High proportion of AG                                                                                                                                                 Good
                    *FGFR1* duplication                      PA, DA, DNT                                                                                                                                                           Good
  HGG               K27M-mutant                              H3.1 and H3.3 K27 mutation, *PDGFRA* focal amplification, *TP53* mutation, *ACVR1* mutation                                                                           Poor
                    G34R/V-mutant                            H3.3 G3 and *TP53* mutation                                                                                                                                           Poor
                    *RTK1* amplified                         *PDGFRA* and *EGFR* focal amplification, *CDKN2A/2B* homozygous deletion                                                                                              Poor
                    Mesenchymal                              *NFI* mutation, *PDGFRA* and *EGFR* focal amplification, *CDKN2A/2B* homozygous deletion                                                                              \-
  Ependymoma        C11orf95-RELA+ (70% of ST E)             *RELA* fusion transcripts                                                                                                                                             Poor
                    RELA fusion - (30% of ST E)              Possibly *YAP1* fusion transcripts                                                                                                                                    Good
                    Posterior fossa E                        Group A: LAMA2 overexpression,                                                                                                                                        Poor
                                                             Group B: NELL2 overexpression                                                                                                                                         Good
                    Spinal cord E (10% of child E)           *NF2* mutation, myxopapillary histology                                                                                                                               Good
  Medulloblastoma   WNT (10%)                                Nuclear β-catenin positive, *CTNNBI* mutations in exon 3, monosomy 6                                                                                                  Excellent
                    SHH (30%)                                Heterogeneous molecular features depending on age of presentation; *PTCH1*, *SMO*, and *SUFU* mutations, *GLI2* and *MYCN* amplification; germline *TP53* mutations   Intermediate (except in infants who have a good prognosis)
                    Group 3 (25%)                            By some unknown mechanism; *MYC* amplification and over expression                                                                                                    Poor
                    Group 4 (35%)                            i(17)q; *MYCN* amplification                                                                                                                                          Intermediate
  AT/RT                                                      SMARCB1/SHARCA4 mutation                                                                                                                                              Poor
  ETMR                                                       *C19MC* amplification                                                                                                                                                 Poor

LGG, low grade glioma; PXA, pleomorphic xanthoastrocytoma; GG, ganglioglioma; DA, diffuse astrocytoma; PA, pilocytic astrocytoma; AG, angiocentric glioma; DNT, dysembryoplastic neuroepithelial tumor; HGG, high grade glioma; ST, supratentorial; PF, posterior fossa; E, ependymoma; WNT, wingless signaling pathway; i, isochromosome; AT/RT, atypical teratoid/rhabdoid tumor; ETMR, embryonal tumor with multilayer rosettes.

###### 

Mutation rate of commonly mutated genes in various brain tumors \[[@b7-jptm-2017-03-08],[@b9-jptm-2017-03-08],[@b48-jptm-2017-03-08],[@b55-jptm-2017-03-08]-[@b57-jptm-2017-03-08],[@b63-jptm-2017-03-08],[@b77-jptm-2017-03-08]-[@b81-jptm-2017-03-08]\]

  Genes and molecules        Biomarker type                           PA (%)   PXA (%)   DA/AA (%)   IDH- wildtype GBM (%)   IDH- mutant GBM (%)   DMG, H3 K27M (%)   ODG (%)   Epen (%)   MB (%)   AT/RT (%)   Test method
  -------------------------- ---------------------------------------- -------- --------- ----------- ----------------------- --------------------- ------------------ --------- ---------- -------- ----------- ------------------------------
  WHO grade                                                           I        II, III   II, III     IV                      IV                    IV                 II/III    II/III     IV       IV          
  *IDH1* mutation            Diagnostic and prognostic                0        \-        \> 80       5-6                     \> 95                 0                  98        0          0        0           IHC, sequencing
  *IDH2* mutation            Diagnostic and prognostic                0        \-                    \-                      2-5                   0                  2         0          0        0           Sequencing
  *TP53* mutation            Diagnostic and prognostic                0        6         94          25-35                   62-65                 45-50              9-44      0          \-       0           Sequencing, IHC
  *ATRX* mutation            Diagnostic and prognostic                         \-        86          0                       90-95                 50                 \-        0          \-       0           IHC, sequencing
  Histone K27M mutation      Diagnostic and prognostic                0        \-        0           Pediatric HGG           0                     100                0         0          0        0           IHC, sequencing
  Histone G34 mutation       Diagnostic and prognostic                0        \-        \-          Uncertain               \-                    \-                 0         0          \-       \-          Sequencing
  Histone K36 mutation       Diagnostic and prognostic                0        \-        \-          \-                      \-                    \-                 0         0          \-       \-          Sequencing
  1p/19q codeletion          Diagnostic, prognostic, and predictive   0        0         0           0                       0                     0                  100       0          0        0           FISH, CGH
  *CIC* mutation             Diagnostic, prognostic, and predictive   0        \-        \-          \-                      \-                    \-                 49        0          \-       \-          Sequencing, IHC
  *FUBP1* mutation           Diagnostic, prognostic, and predictive   0        \-        \-          \-                      \-                    \-                 29        0          \-       \-          Sequencing, IHC
  *EGFR* amp                 Prognostic                               0        \-        \-          35-45                   4                     \-                 \-        0          \-       \-          FISH, CGH, IHC
  *PDGFRA* amp               Diagnostic                                        \-        \-          13                      \-                    50                 \-                   \-       \-          FISH, CGH, IHC
  *PTEN* HoD                 Prognostic                               0        \-        \-          25-35                   5                     \-                 \-        0          \-       \-          FISH, CGH, IHC
  *CDKN2A* HoD               Predictive                               0        60        11          35-50                   \-                    \< 5               \-        0          \-       \-          FISH, CGH, IHC
  *BRAF* V600E mutation      Diagnostic and prognostic                15       67        0           1-2                     0                     0                  0         0          0        0           Sequencing, IHC
  *BRAF-KIAA1549* fusion     Diagnostic and prognostic                70       \-        \-          \-                      \-                    \-                 \-        \-         \-       \-          RT-PCR, FISH (gain)
  *TERT* promoter mutation   Diagnostic and prognostic                \-       \-        \-          \> 80                   26                    \-                 96        0          21       \-          Sequencing
  *C11orm-RELA* fusion       Diagnostic and prognostic                0        \-        \-          \-                      \-                    \-                 \-        \<5        \-       \-          RT-PCR, IHC, RNA seq
  β-Catenin mutation         Diagnostic and prognostic                0        \-        \-          \-                      \-                    \-                 \-        0          6-9      \-          IHC, sequencing
  *MYC* amp                  Prognostic                               0        \-        \-          \-                      \-                    \-                 \-        \-         10--15   \-          FISH, CGH, IHC
  *MYCN* amp                 Prognostic                               0        \-        \-          \-                      \-                    \-                 \-        \-         10--15   \-          FISH, CGH
  *SMARCB1* mutation         Diagnostic and prognostic                0        \-        \-          \-                      \-                    \-                 \-        0          0        98          IHC, sequencing
  *SMARCA4* mutation         Diagnostic and prognostic                0        \-        \-          \-                      \-                    \-                 \-        0          0        1-2         IHC, sequencing
  *MGMT* methylation         Predictive                               \-       \-        78.5        48.5                    60-80                 \-                 85        0          0        0           MSP-PCR, pyrosequencing, IHC

PA, pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; DA, diffuse astrocytoma; AA, anaplastic astrocytoma; GBM, glioblastoma; DMG, diffuse midline glioma; HGG, high grade glioma; ODG, oligodendroglioma; MB, medulloblastomas; AT/RT, atypical teratoid/ rhabdoid tumor; WHO, World Health Organization; IHC, immunohistochemistry; FISH, fluorescent *in situ* hybridization; CGH, comparative genomic hybridization; RT-PCR, reverse transcription polymerase chain reaction; -, not known; MSP-PCR, methylation-specific polymerase chain reaction.

###### 

Summary of the mutation specific antibodies and their indication in glioma diagnosis \[[@b12-jptm-2017-03-08],[@b36-jptm-2017-03-08],[@b48-jptm-2017-03-08],[@b81-jptm-2017-03-08],[@b84-jptm-2017-03-08]\]

  Antibody                Positive loci           Mutated gene status         Positive result   Tumors
  ----------------------- ----------------------- --------------------------- ----------------- ----------------------------------------------------------------------------------------------------------------------------
  ATRX                    Nucleus                 Loss of function mutation   Negative          Diffuse and anaplastic astrocytoma
  β-Catenin               Nucleus                 Gain of function mutation   Focal positive    WNT type medulloblastoma, adamantinomatous craniopharyngioma
  BRAF VE1 (BRAF V600E)   Cytoplasm               Gain of function mutation   Positive          Pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, epithelioid glioblastoma, papillary craniopharyngioma
  BRG1                    Nucleus                 Gain of function mutation   Negative          Atypical teratoid rhabdoid tumor
  CIC                     Nucleus                 Loss of function mutation   Negative          Oligodendroglioma (47%) \[[@b15-jptm-2017-03-08]\]
  c-MET                   Membrane                Overexpression              Positive          Glioblastoma, anaplastic astrocytoma
  EGFR                    Membrane                Overexpression              Positive          Glioblastoma, anaplastic astrocytoma
  EGFRvIII                Membrane                Overexpression              Positive          Glioblastoma, anaplastic astrocytoma
  H3 K27M                 Nucleus                 Gain of function mutation   Positive          Diffuse midline glioma
  FUBP1                   Nucleus                 Loss of function mutation   Negative          Oligodendroglioma (16%) \[[@b15-jptm-2017-03-08]\]
  IDH1 (H09)              Nucleus and cytoplasm   Gain of function mutation   Positive          Astrocytoma and oligodendroglioma
  INI1                    Nucleus                 Loss of function mutation   Negative          Atypical teratoid rhabdoid tumor
  P16                     Nucleus and cytoplasm   Loss of function mutation   Negative          High grade glioma
  P53                     Nucleus                 Overexpression              Positive          Astrocytic tumors
  PDGFRA                  Membrane                Overexpression              Positive          Glioblastoma, anaplastic astrocytoma
  PTEN                    Cytoplasm               Loss of function mutation   Negative          Glioblastoma
  RELA (NFKB3)            Cytoplasm               Gain of function mutation   Positive          Cerebral ependymoma
  STAT6                   Nucleus                 Gain of function mutation   Positive          Solitary fibrous tumor/hemangiopericytoma
  MLH1                    Nucleus                 Loss of function mutation   Negative          Gliomas
  MSH2                    Nucleus                 Loss of function mutation   Negative          Gliomas
  PMS2                    Nucleus                 Loss of function mutation   Negative          Gliomas
  Ki67                    Nucleus                 Overexpression              Positive          Brain tumors (for an ancillary test for tumor grading)
  pHH3                    Nucleus                 Overexpression              Positive          Brain tumors (for counting mitoses)
  GFAP                    Nucleus                 Expression                  Positive          Astrocytic tumors
  Olig2                   Nucleus                 Expression                  Positive          Gliomas including astrocytomas and oligodendroglioma
                                                                                                Neither neuronal nor ependymal tumors

###### 

The current sequencing conditions commonly used for brain tumor diagnosis \[[@b35-jptm-2017-03-08],[@b45-jptm-2017-03-08],[@b59-jptm-2017-03-08],[@b68-jptm-2017-03-08],[@b84-jptm-2017-03-08],[@b91-jptm-2017-03-08],[@b92-jptm-2017-03-08]\]

  Gene                                        Full name                                        Gene location   Forward primer                                                     Reverse primer                                                    Product (bp)   Indication                                                               Function
  ------------------------------------------- ------------------------------------------------ --------------- ------------------------------------------------------------------ ----------------------------------------------------------------- -------------- ------------------------------------------------------------------------ -------------------------------------------------------
  *IDH1*                                      Isocitrate dehydrogenase 1                       2q33.3          5´-M13-GTA AAA CGA CGG CCA GTC GGT CTT CAG AGA AGC CA-3´           5´-GCG GAT AAC AAT TTC ACA CAG GGC AAA ATC ACA TTA TTG C-3´       180--190       Astrocytic and ODG                                                       Affect citrate metabolism, leading to 2-HG metabolite
  *IDH2*                                      Isocitrate dehydrogenase 2                       15q26.1         5´-GCT GCA GTG GGA CCA CTA TT-3´                                   5´-TGT GGC GTT GTA CTG CAG AG-3´                                  295--305       Astrocytic and ODG                                                       Same with IDH1
  *H3F3A* (K27M/K36/G34)                      H3 Histone family 3A                             1q42.12         5´-CTG GTA AAG CAC CCA GGA AGC-3´                                  5´-CAT GGA TAG CAC ACA GGT TGG T-3´                               330--340       DMG                                                                      Chromatin structure, gene transcription
  *BRAF* V600E                                V-RAF murine sarcoma viral oncogene homolog B1   7q34            1st: 5´-GCT TGC TCT GAT AGG AAA ATG AG-3´                          1st: 5´-GTA ACT CAG CAG CAT CTC AGG-3´                            245--255       Gliomas including PXA, GG, PA, epithelioid GBM                           MAPK signaling
  2nd: 5´-TCA TAA TGC TTG CTC TGA TAG GA-3´   2nd: 5´-GGC CAA AAA TTT AAT CAG TGG A-3´         230--235                                                                                                                                                                                                                                     
  *CTNNB1*                                    Catenin, beta-1                                  3p22.1          5´-GAT TTG ATG GAG TTG GAC ATG G-3´                                5´-TGT TCT TGA GTG AAG GAC TGA G-3´                               230--235       Medulloblastoma, WNT subtype, craniopharyngioma, adamantinomatous type   The transmission of the 'contact inhibition' signal
  *TERTp*                                     Telomerase reverse transcriptase                 5p15.33         5´-M13-GGC CGA TTC GAC CTC TCT-3´ (M13: TGT AAA ACG ACG GCC AGT)   5´-AGC ACC TCG CGG TAG TGG-3´ (M13: GCG GAT AAC AAT TTC ACA CA)   300--310       Gliomas, especially ODG and GBM                                          Telomerase maintenance
  *MGMT*                                      O6 mentylguanine-DNA methyltransferase           10q26.3         5´-TTT CGA CGT TCG TAG GTT TTC GC-3´                               5´-GCA CTC TTC CGA AAA CGA AAC G-3´                               80--90         Gliomas                                                                  Promoter methylation

ODG, oligodendroglioma; 2-HG, 2-hydroxyglutamate; DMG, diffuse midline glioma; PXA, pleomorphic xanthoastrocytoma; GG, ganglioglioma; PA, pilocytic astrocytoma; GBM, glioblastoma; MAPK, mitogen-activated protein kinase.

###### 

Probes and reading criteria of FISH studies used for brain tumor diagnosis

                                                     Target probe   Control   Cut off                                Indication     Biomarker
  -------------------------------------------------- -------------- --------- -------------------------------------- -------------- ----------------------------------------
  1p deletion                                        Chr1p36        1q25      1p \< 0.8 and Deleted nuclei \> 50%    ODG            Diagnostic, prognostic, and predictive
  19q deletion                                       Chr19q13       19p13     19q \< 0.8 and Deleted nuclei \> 50%   ODG, HGG       Diagnostic, prognostic, and predictive
  *BRAF* gain                                        Chr7q34        CEP7      Gold signal \> 3                       PA             Diagnostic, prognostic, and predictive
  *CDKN2A* (9p21.3) homozygous/hemizygous deletion   Chr9p21.3      CEP9      HoD ≥ 10%                              HGG            Diagnostic and prognostic
  HeD ≥ 50%                                                                                                                         
  *EGFR* amplification                               Chr711.2       CEP7      Ratio ≥ 2.0                            HGG            Diagnostic and prognostic
  *PTEN* HoD /HeD                                    Chr10q23.31    CEP10     HoD ≥ 10%                              HGG            Diagnostic and prognostic
  HeD ≥ 50%                                                                                                                         
  *RELA-C11orf95* fusion                             Chr11q13.1     CEP11     Break apart                            S-ependymoma   Diagnostic and prognostic
  *C19MC* amplification                              Chr19          CEP19     Ratio ≥ 2.0                            ODG, GBM       Diagnostic and prognostic
  SMARCB1                                            Chr22q11.23    CEP22     NF2 \< 0.8                             AT/RT          Diagnostic and prognostic

FISH, fluorescent *in situ* hybridization; Chr, chromosome; ODG, oligodendroglioma; HGG, high grade glioma; PA, pilocytic astrocytoma; HoD, homozygous deletion; HeD, hemizygous deletion; S-ependymoma, supratentorial ependymoma; GBM, glioblastoma; AT/RT, atypical teratoid/rhabdoid tumor.
